Author:
SUN Wenjia,ZHENG Jing,ZHOU Jianya,ZHOU Jianying
Publisher
China Science Publishing & Media Ltd.
Reference56 articles.
1. SUNG H, FERLAY J, SIEGEL R L. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71: 209-249.
2. SODA M, CHOI Y L, ENOMOTO M. Iden-tification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448: 561-566.
3. RODIG S J, SHAPIRO G I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases[J]. Curr Opin Investig Drugs, 2010, 11(12): 1477-1490..
4. CHEN H F, WANG W X, XU C W. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib. Lung Cancer, 2020, 142: 59-62.
5. SUH C H, KIM K W. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis. Lung Cancer, 2019, 132: 79-86.